FDA Approves Treatment for COVID-19 in Adults

On May 25, 2023 the U.S. Food and Drug Administration (FDA) approved the first oral antiviral pill to treat mild-to-moderate COVID-19 in adult patients who have underlying conditions or are at high risk of complications from COVID.

This medication, called Paxlovid, was originally available under the emergency use authorization (EUA) and was made available through the U.S. Department of Health and Human Services. As of the writing of this post, the United States government will continue to make Paxlovid available to U.S. residents at no charge.

For more information about the approval of Paxlovid, please visit the FDA website or speak with your doctor or pharmacist.